Resources to be in place for effective Covid-19 vaccination: NITI VC

Niti Aayog Vice Chairman Rajiv Kumar expressed confidence that money and resources will be in place for a viable and effective Covid-19 vaccination system

Vaccine
Press Trust of India New Delhi
3 min read Last Updated : Oct 22 2020 | 11:25 PM IST

Niti Aayog Vice Chairman Rajiv Kumar on Thursday expressed confidence that money and resources will be in place for a viable and effective vaccination system to fight COVID-19, even as he said it is quite premature to talk about the cost for getting the vaccination.

Participating in a virtual event organised by Public Affairs Forum of India (PAFI),Kumar expressed hope that the corporate world will also rise up to the occasion and make the vaccination part of their CSR activity.

Responding to a question about money required on procuring and distribution of vaccines, he said, "I think it is very premature at the moment to talk about costs, funds and resources required for getting the vaccination... That will depend entirely on what the modalities are, how we go about it."

"Yes, it will cost resources, I think given the lead the prime minister has given, I don't think that (cost) will come in the way of putting in place a viable, effective vaccination system," he said.

AdarPoonawalla, Chief Executive Officer of Serum Institute of India (SII) which is producing the potential coronavirusvaccine developed by Oxford University, had asked if the government will have Rs 80,00 crore available to buy and distribute the vaccine.

Kumar further said that "at the same time, we have to make sure we have unique IDs of those who have been given the vaccination, (and) make it portable so that it can be shown as evidence wherever you travel", adding that it's a huge effort, and theNitiAayog withNandanNilkeniis trying to figure it out.

"Then we need to decide whether we go for senior citizens first, or you want to go to the working population," theNitiAayogvice chairman said.

He also noted that it is more important to focus on "getting the mechanism right, getting the mechanism in place, to get unique ID, to get portable ID, to get universal coverage".

Kumaralso pointed out that Serum Institute of India (SII) will not be the only company which will produce the vaccine, there are others also.

"I am sure, the corporate world will also rise upto the occasion and make it part of their CSR activity, (and) not charge profit for that," he said.

Union Finance MinisterNirmalaSitharamanThursday released theBJP'smanifesto for theBiharassembly polls which promised freeCOVID-19 vaccine once it has been cleared by theICMR.

NitiAayogmember V K Paul is heading the National Expert Group on Vaccine Administration forCOVID-19 (NEGVAC).

Paul, who is also the chief of an expert panel coordinating efforts to tackle the pandemic in the country, in an interview toPTIhad said that once theCOVID-19 vaccine is available, there will be enough resources to deliver as well as make it accessible to the citizens.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Oct 22 2020 | 11:20 PM IST

Next Story